Journey Medical Corp (DERM)
3.93
+0.13
(+3.42%)
USD |
NASDAQ |
May 31, 16:00
3.93
0.00 (0.00%)
After-Hours: 20:00
Journey Medical SG&A Expense (Quarterly): 8.42M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 8.42M |
December 31, 2023 | 9.841M |
September 30, 2023 | 8.636M |
June 30, 2023 | 12.14M |
March 31, 2023 | 13.29M |
December 31, 2022 | 13.99M |
September 30, 2022 | 15.58M |
June 30, 2022 | 15.19M |
Date | Value |
---|---|
March 31, 2022 | 14.72M |
December 31, 2021 | 15.06M |
September 30, 2021 | 10.76M |
June 30, 2021 | 7.795M |
March 31, 2021 | 6.226M |
December 31, 2020 | 5.816M |
September 30, 2020 | 5.829M |
June 30, 2020 | 4.752M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
4.752M
Minimum
Jun 2020
15.58M
Maximum
Sep 2022
10.50M
Average
10.30M
Median
SG&A Expense (Quarterly) Benchmarks
Fortress Biotech Inc | 17.94M |
Stereotaxis Inc | 6.469M |
GT Biopharma Inc | 2.314M |
Cara Therapeutics Inc | 6.786M |
FibroGen Inc | 22.82M |